Peter Wolfe
Infectious Disease · Los Angeles, CANPI 1407910201
Payments from drug & device makers
Across 537 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$6K
- Gilead$1K
- EMD Serono, Inc.$1K
- Napo Pharmaceuticals Inc$823
- Merck$419
- Johnson & Johnson$409
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$851%
- Food & beverage$12,30999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 225 | $5,501 |
| Gilead | 43 | $1,267 |
| EMD Serono, Inc. | 44 | $1,099 |
| Napo Pharmaceuticals Inc | 38 | $823 |
| Merck | 15 | $419 |
| Johnson & Johnson(2 entities) | 25 | $409 |
| Amgen | 19 | $383 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $305 |
| Antares Pharma, Inc. | 17 | $289 |
| Bausch Health US, LLC | 15 | $288 |
| Theratechnologies Inc. | 9 | $275 |
| Lilly USA, LLC | 14 | $222 |
| AstraZeneca | 11 | $192 |
| AbbVie(2 entities) | 8 | $165 |
| GSK | 9 | $156 |
| Idorsia Pharmaceuticals US Inc | 6 | $101 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $79 |
| Halozyme Inc | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Exact Sciences | 2 | $40 |
| Novo Nordisk | 2 | $34 |
| Tolmar, Inc. | 2 | $33 |
| Pfizer | 2 | $32 |
| Boston Scientific | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| Seqirus USA Inc | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,393 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 99 | $383,750 |
| IsentressRaltegravir Potassium | 79 | $162,537 |
| DescovyEmtricitabine/Tenofov Alafenam | 70 | $157,102 |
| TivicayDolutegravir Sodium | 49 | $109,699 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 19 | $88,187 |
| PrezcobixDarunavir/Cobicistat | 31 | $84,706 |
| Darunavir | 69 | $73,576 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $73,030 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 14 | $67,735 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 13 | $48,611 |
| JulucaDolutegravir/Rilpivirine | 12 | $41,420 |
| Maraviroc | 29 | $40,306 |
| Etravirine | 32 | $34,105 |
| Atazanavir Sulfate | 42 | $22,091 |
| Ritonavir | 92 | $12,885 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $1,267 | $608,587183 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Juluca | $5,501 | $199,73074 claims |
| MerckIsentress | $419 | $162,53779 claims |
| Johnson & JohnsonPrezcobix | $409 | $84,70631 claims |
| PfizerEliquis | $32 | $11,78620 claims |
| AbbVieLumigan | $165 | $3,45914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.
Other infectious disease in Los Angeles
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Jay GladsteinLos Angeles$4M
- Jesse ClarkLos Angeles$2M
- Jeffrey KlausnerLos Angeles$1.2M
- Otto YangLos Angeles$1.1M
- Michael DubeLos Angeles$742K
- Drew WinstonLos Angeles$697K
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.